Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Noninvasive markers of liver fibrosis in drug users with Hep C

FibroSURE, alanine aminotransferase, and aminotransferase-to-platelet-ratio index tests predict insignificant fibrosis in injection drug users with Hep C, reports this month's Hepatology.

News image

Most Hepatitis C virus infections are acquired by injection drug use.

Dr Lucy Wilson and colleagues from the USA assessed prospective data on the progression of liver fibrosis.

Baseline liver biopsies were obtained from 1996 to 1998 on a random sample of 210 out of 1667 Hepatitis C virus-positive injection drug users.

Subjects were followed biannually, with a second biopsy offered to those eligible.

Among 119 prospectively followed injection drug users, 96% were African American, and 97% were Hepatitis C virus genotype 1a/b.

A further 27% were HIV-infected, with a median age of 42 years.

Paired biopsies were scored from 0 to 6.

The research team defined significant fibrosis was as score 3 or greater.

Progression of fibrosis was defined as an increase 2 or more units or clinical evidence of end-stage liver disease.

The predictive value for alanine aminotransferase specificities was 73%
Hepatology

The team's predictive values of blood markers include FibroSURE, aspartate aminotransferase-to-platelet-ratio index and alanine aminotransferase.

The researchers assessed the detection of contemporaneous and future liver fibrosis.

The team noted that 91% did not have significant liver fibrosis at first biopsy.

The researchers' predictive value for detecting insignificant fibrosis at first biopsy was greater than 95% for FibroSURE.

The predictive value for aminotransferase-to-platelet-ratio index, and alanine aminotransferase specificities were 73%.

After 4 years median follow-up, 21% had progression of fibrosis.

The researchers observed that this was significantly associated with serum level of Hepatitis C virus RNA and alanine aminotransferase.

No serological test had a predictive value greater than 40% for contemporaneous or future significant fibrosis.

Initial biopsy result had only a 30% value for predicting future significant fibrosis.

Dr Wilson's team concluded, “Significant liver fibrosis and progression were detected in some, but not most, injection drug users in this cohort.”

“In this setting with low fibrosis prevalence, FibroSURE, alanine aminotransferase, and aminotransferase-to-platelet-ratio index tests predict insignificant fibrosis.”

“However, further work is needed to find noninvasive markers of significant liver fibrosis.”

Hepatol 2006: 43(4): 788-95
05 April 2006

Go to top of page Email this page Email this page to a colleague

 18 September 2014

Advanced search
 18 September 2014 
Patient improvement following sacral neuromodulation
 18 September 2014 
Autoimmune diseases in functional gastrointestinal disorders
 18 September 2014 
New diagnostic score for hepatic steatosis
 17 September 2014 
Orange juice intake for bowel preparation
 17 September 2014 
Treatment of fistulising perianal Crohn's disease
 17 September 2014 
Interval colorectal cancers
 16 September 2014 
Fiber treats IBS
 16 September 2014 
Resected biliary tract cancer
 16 September 2014 
Postoperative adhesions in digestive surgery
 15 September 2014 
Prunes and GI function
 15 September 2014 
Fecal transplantation for C.diff infection
 15 September 2014 
Antidepressants for IBS
 12 September 2014 
Management of complex colon polyps
 12 September 2014 
Metabolic syndrome delays HBeAg seroclearance
 12 September 2014 
Drug-induced liver disease
 11 September 2014 
Hepatobiliary cirrhosis risk after organ transplant
 11 September 2014 
Sofosbuvir plus peginterferon/ribavirin for HCV
 11 September 2014 
Patient perceptions in celiac disease
 10 September 2014 
Adhesions in abdominal and pelvic surgery
 10 September 2014 
Acute kidney injury after colonoscopy
 10 September 2014 
Management algorithm for endoscopic mucosal resection of colonic lesions
 09 September 2014 
Neutrophil function and mortality in cirrhosis
 09 September 2014 
PPIs and spontaneous bacterial peritonitis in cirrhosis
 09 September 2014 
MELD and liver cancer survival
 08 September 2014 
Vagal nerve blockade and morbid obesity
 08 September 2014 
Comparison of diet programs in overweight and obese adults
 08 September 2014 
Long-term follow-up after bariatric surgery
 05 September 2014 
Healing rates in reflux esophagitis
 05 September 2014 
Progression of environmental enteropathy
 05 September 2014 
Diabetes and liver transplant outcomes
 04 September 2014 
Colectomy rates for refractory ulcerative colitis
 04 September 2014 
Infliximab prevents long-term Crohn’s disease recurrence
 04 September 2014 
Histological recovery with gluten-free diet in celiac disease
 03 September 2014 
Diagnosis of atrophic gastritis
 03 September 2014 
Predictors of response in Crohn's disease
 03 September 2014 
Safety of reinitiation of infliximab therapy
 02 September 2014 
SSRIs and depression in Hep C
 02 September 2014 
Bariatric surgery for obesity
 02 September 2014 
Eosinophilic esophagitis in adults
 01 September 2014 
Risks with anti-TNF in pediatric IBD
 01 September 2014 
Fecal hemoglobin and colorectal cancer screening
 01 September 2014 
Genetic variants in alcoholic liver disease
 29 August 2014 
Gluten-free diet for asymptomatic celiac disease
 29 August 2014 
NSAID-induced small intestinal injury and diaphragm disease
 29 August 2014 
Symptom evaluation in functional dyspepsia
 28 August 2014 
Predictoris of C. diff in out-patients
 28 August 2014 
Detection of gastroesophageal reflux symptoms
 28 August 2014 
Colorectal-cancer mortality after adenoma removal
 27 August 2014 
Endoscopy outcomes in community hospital vs tertiary academic centers
 27 August 2014 
UV exposure and IBD hospitalizations
 27 August 2014 
Hepatocellular carcinoma screening in liver disease
 26 August 2014 
NAFLD and gastroesophageal reflux symptoms
 26 August 2014 
Adalimumab-treated patients with ulcerative colitis
 26 August 2014 
Wound healing after abdominoperineal resection
 25 August 2014 
Surgical management of rectourethral fistulas
 25 August 2014 
Biomarker analysis in biopsies for ulcerative colitis
 25 August 2014 
Ileocolic resection in Crohn's disease
 22 August 2014 
Outlier identification in colorectal surgery
 22 August 2014 
Endoscopic submucosal dissection for squamous esophageal cancer
 22 August 2014 
Adherence to Rome criteria in functional dyspepsia trials

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2014 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us